Back to GetFilings.com
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(MARK ONE)
/X/ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 1995
OR
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________ TO
_____________
COMMISSION FILE NUMBER 1-4448
- --------------------------------------------------------------------------------
[LOGO]
Baxter International Inc.
- --------------------------------------------------------------------------------
DELAWARE 36-0781620
- ----------------------- --------------------------------
State of Incorporation I.R.S. Employer Identification
No.
ONE BAXTER PARKWAY, DEERFIELD, ILLINOIS 60015
(847) 948-2000
--------------------------------------------------
Address, including zip code, and telephone number,
including area code, of principal executive offices
Securities registered pursuant to Section 12(b) of the Act:
NAME OF EACH EXCHANGE
TITLE OF EACH CLASS ON WHICH REGISTERED
- ----------------------------------- -------------------------
Common stock, $1 par value New York Stock Exchange
Chicago Stock Exchange
Pacific Stock Exchange
Preferred Stock Purchase Rights New York Stock Exchange
(currently traded with common Chicago Stock Exchange
stock) Pacific Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
--------------------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes _X_ No ____
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein and will not be contained, to the
best of registrant's knowledge, in the definitive proxy statement incorporated
by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
/ /
The aggregate market value of the voting stock held by non-affiliates of the
registrant (based on the per share closing sale price of $43.88 on March 8,
1996, and for the purpose of this computation only, the assumption that all
registrant's directors and executive officers are affiliates) was approximately
$11.8 billion.
The number of shares of the registrant's common stock, $1 par value,
outstanding as of March 8, 1996, was 273,957,449.
DOCUMENTS INCORPORATED BY REFERENCE
Those sections or portions of the registrant's 1995 annual report to
stockholders and of the registrant's proxy statement for use in connection with
its annual meeting of stockholders to be held on May 6, 1996, described in the
cross reference sheet and table of contents attached hereto are incorporated by
reference in this report.
- --------------------------------------------------------------------------------
CROSS REFERENCE SHEET
AND
TABLE OF CONTENTS
- --------------------------------------------------------------------------------
PAGE NUMBER OR
(REFERENCE) (1)
-----------------
Item 1. Business
(a) General Development of Business................................................. 3(2)
(b) Financial Information about Industry Segments................................... 3(3)
(c) Narrative Description of Business............................................... 3(4)
(d) Financial Information about Foreign and Domestic Operations and Export Sales.... 8(5)
Item 2. Properties................................................................................. 9
Item 3. Legal Proceedings.......................................................................... 9(6)
Item 4. Submission of Matters to a Vote of Security Holders........................................ 9
Item 5. Market for the Registrant's Common Equity and Related Stockholder
Matters.................................................................................... 10(7)
Item 6. Selected Financial Data.................................................................... 10(8)
Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations.............................................................................. 10(9)
Item 8. Financial Statements and Supplementary Data................................................ 10(10)
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure....................................................................... 10
Item 10. Directors and Executive Officers of the Registrant
(a) Identification of Directors..................................................... 11(11)
(b) Identification of Executive Officers............................................ 11
(c) Compliance with Section 16(a) of the Securities Exchange Act of 1934............ 13(12)
Item 11. Executive Compensation..................................................................... 13(13)
Item 12. Security Ownership of Certain Beneficial Owners and Management............................. 13(14)
Item 13. Certain Relationships and Related Transactions............................................. 13
Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-K............................ 14
(a) Financial Statements............................................................ 14
(b) Reports on Form 8-K............................................................. 14
(c) Exhibits........................................................................ 14
- ------------------------
(1) Information incorporated by reference to the Company's Annual Report to
Stockholders for the year ended December 31, 1995 ("Annual Report") and
the board of directors' proxy statement for use in connection with the
Registrant's annual meeting of stockholders to be held May 6, 1996 ("Proxy
Statement").
(2) Annual Report, pages 50-70, section entitled "Notes to Consolidated
Financial Statements" and pages 30-43, section entitled "Management's
Discussion and Analysis."
(3) Annual Report, pages 68-69, section entitled "Notes to Consolidated
Financial Statements-- Industry and Geographic Information."
(4) Annual Report, pages 30-43, section entitled "Management's Discussion and
Analysis" and pages 68-69, section entitled "Notes to Consolidated
Financial Statements--Industry and Geographic Information."
(5) Annual Report, pages 68-69, section entitled "Notes to Consolidated
Financial Statements-- Industry and Geographic Information."
(6) Annual Report, page 62-68, section entitled "Notes to Consolidated
Financial Statements-- Legal Proceedings."
(7) Annual Report, page 70, section entitled "Notes to Consolidated Financial
Statements--Quarterly Financial Results and Market for the Company's
Stock."
(8) Annual Report, inside back cover, section entitled "Five-Year Summary of
Selected Financial Data."
(9) Annual Report, pages 30-43, section entitled "Management's Discussion and
Analysis."
(10) Annual Report, pages 45-70, sections entitled "Report of Independent
Accountants," "Consolidated Balance Sheets," "Consolidated Statements of
Income," "Consolidated Statements of Cash Flows," "Consolidated Statements
of Stockholders' Equity" and "Notes to Consolidated Financial Statements."
(11) Proxy Statement, pages 2-5, sections entitled "Board of Directors" and
"Election of Directors."
(12) Proxy Statement, page 18, section entitled "Section 16 Reporting."
(13) Proxy Statement, pages 6-12, sections entitled "Compensation of Directors"
and "Compensation of Named Executive Officers," and page 17-18, section
entitled "Pension Plan, Excess Plans and Supplemental Plans."
(14) Proxy Statement, pages 18-20, section entitled "Ownership of Company
Securities."
- --------------------------------------------------------------------------------
[BAXTER LOGO]
Baxter International Inc., One Baxter Parkway, Deerfield. Illinois 60015.
- --------------------------------------------------------------------------------
PART I
- --------------------------------------------------------------------------------
ITEM 1. BUSINESS.
(a) GENERAL DEVELOPMENT OF BUSINESS.
Baxter International Inc. was incorporated under Delaware law in 1931. As
used in this report, except as otherwise indicated in information incorporated
by reference, "Baxter" means Baxter International Inc. and the "Company" means
Baxter and its subsidiaries.
The Company is engaged in the worldwide development, distribution and
manufacture of a diversified line of products, systems and services used
primarily in the health-care field. Products are manufactured by the Company in
23 countries and sold in approximately 100 countries. Health-care is concerned
with the preservation of health and with the diagnosis, cure, mitigation and
treatment of disease and body defects and deficiencies. The Company's more than
200,000 products are used by hospitals, clinical and medical research
laboratories, blood and dialysis centers, rehabilitation centers, nursing homes,
doctors' offices and at home under physician supervision. See "Recent
Developments."
For information regarding acquisitions, investments in affiliates and
divestitures, see the Company's Annual Report to Stockholders for the year ended
December 31, 1995 (the "Annual Report"), page 53, section entitled "Notes to
Consolidated Financial Statements--Acquisitions, Investments in Affiliates and
Divestitures" which is incorporated by reference.
(b) FINANCIAL INFORMATION ABOUT INDUSTRY SEGMENTS.
Incorporated by reference from the Annual Report, pages 68-69, section
entitled "Notes to Consolidated Financial Statements--Industry and Geographic
Information."
(c) NARRATIVE DESCRIPTION OF BUSINESS.
Recent Developments
SPIN-OFF OF HEALTH CARE COST MANAGEMENT BUSINESS
On November 28, 1995, the board of directors of Baxter approved in principle
a plan to distribute to Baxter stockholders all of the outstanding stock of its
health-care cost management business in a spin-off transaction (the
"Distribution") which is expected to be tax-free. The creation of two
independent companies will enable Baxter and the new company to devote
management time, attention and investments directly to the core strategies of
each business. The new health-care cost management business will consist of the
Company's cost management services, United States distribution, surgical
products and respiratory-therapy operations and will operate as a medical
supplier focused on helping customers manage the total cost of providing patient
care. The Distribution is expected to occur in late 1996 and will result in the
health-care cost management business operating as an independent entity with
publicly-traded common stock.
OFFER TO ACQUIRE NATIONAL MEDICAL CARE; SUBSEQUENT WITHDRAWAL
On February 1, 1996, Baxter publicly announced its proposal to acquire the
National Medical Care ("NMC") subsidiary of W.R. Grace and Company ("Grace") in
a tax-free transaction for $3.8 billion, consisting of $1.8 billion of Baxter
common stock and a payment to Grace of $2.0 billion comprised of cash, notes and
assumed debt. Grace had previously announced its intention to spin-off or divest
NMC. Completion of this transaction in 1996 would have resulted in a dilution of
Baxter's net earnings, but
3
would have been accretive after approximately six quarters of combined results.
The Company's net-debt-to-net-capital ratio would have risen to approximately
42% (compared to 36.3% at December 31, 1995) but was expected to decline to
approximately 40% within two years of the acquisition, all else remaining
constant.
On February 5, 1996, Grace announced that it had agreed to combine its NMC
subsidiary with the worldwide dialysis business of Fresenius A.G. (a German
company) to form a new company called Fresenius Medical Care in a transaction
designed to be tax-free. Fresenius A.G. is a major competitor of the Company's
renal division and NMC is a large United States customer of the renal division.
Under the proposed transaction with Fresenius A.G., Grace shareholders would
receive a 44.8% equity interest in Fresenius Medical Care and Grace would
receive $2.3 billion in cash provided by proceeds of debt financing by Fresenius
Medical Care. This transaction is subject to the approval of the shareholders of
Grace, Fresenius U.S.A. and Fresenius A.G. If the transaction with Grace is
consummated with Fresenius A.G., there will be an increased competitive threat
to the Company's renal division. However, management believes that this would
not have a material adverse effect on Baxter's financial condition or results of
operations in 1996.
Since the management of Grace refused to discuss the Company's proposed
transaction, Baxter withdrew its offer on February 22, 1996.
RESTRUCTURING PROGRAMS
The Company currently has two restructuring programs in process. In November
1993, the Company initiated a restructuring program designed to accelerate
growth and reduce costs in the Company's businesses worldwide, including
reorganizations and consolidations in the United States, Europe, Japan and
Canada. In the third quarter of 1995, the Company initiated a second
restructuring program to consolidate manufacturing operations in Puerto Rico in
order to eliminate excess capacity and reduce manufacturing costs.
Since the announcement of the 1993 restructuring program, the Company has
implemented, or is in the process of implementing, all of the major strategic
actions associated therewith and is satisfied that the program is progressing on
schedule and will meet previously established financial targets. During 1995,
the Company utilized $60 million of restructuring reserves related to its
continuing operations, including $36 million in cash payments. Cash outflows
pertain primarily to employee-related costs for severance, outplacement
assistance, relocation and retention. The Company has eliminated from continuing
operations approximately 1,250 positions of the approximately 1,640 positions
affected by the program. The majority of the remaining reductions will occur in
1996 and 1997, as facility closures and consolidations are completed as planned.
During 1995, the Company realized approximately $90 million in continuing
operations savings which represents a shortfall of approximately $20 million
from its estimated savings target. This shortfall is primarily due to timing
delays in the implementation of a number of projects. Management has forecasted
continuing operations savings of approximately $110 million in 1996, $130
million in 1997 and exceeding $140 million in 1998. Management anticipates that
these savings will be partially invested in increased research and development
and expansion into growing international markets. Management further believes
that its remaining restructuring reserves are adequate to complete the actions
contemplated by the 1993 restructuring program.
Management is at the very early stages of implementing the 1995
restructuring program, which is expected to be completed by the end of 1998. The
pretax restructuring charge of $93 million includes approximately $67 million
for valuation adjustments as a result of the Company's decision to close
facilities.
The Company expects to spend approximately $26 million in cash over the next
two years, including severance related to the approximately 1,450 positions that
will be eliminated in connection with the 1995 plan. The plant closures and
consolidations in Puerto Rico will lower the Company's manufacturing costs.
Management believes these actions will help mitigate the Company's exposure to
future gross
4
margin erosion arising from pricing pressure, primarily in the United States. In
addition to the consolidation of the Company's manufacturing operations in
Puerto Rico, the Company has initiated plans for other organizational structure
changes which have resulted in a $10 million provision for cash payments related
to employee severance.
Management anticipates that future cash expenditures related to both the
1993 and 1995 restructuring programs will be funded from cash generated from
operations.
Industry Overview
The Company operates in a single industry segment as a world leader in
providing health-care products for use in hospitals and other health-care
settings. On a global basis, the Company develops, manufactures and markets
intravenous solutions and related administration equipment, and highly
specialized medical products for treating kidney and heart disease, blood
disorders, and for collecting and processing blood. These products include
intravenous solutions and pumps; dialysis equipment and supplies; prosthetic
heart valves and cardiac catheters; blood-clotting therapies; and machines and
supplies for collecting, separating and storing blood. These products require
extensive research and development and investment in worldwide manufacturing,
marketing and administrative infrastructure.
Information about segment operating results is incorporated by reference
from the Annual Report, pages 30-43, section entitled "Management's Discussion
and Analysis" and pages 68-69, section entitled "Notes to Consolidated Financial
Statements--Industry and Geographic Information."
UNITED STATES MARKETS
Though the federal government failed to enact health-care reform,
fundamental change continued to be a part of the United States health-care
system in 1995. Competition for patients among health-care providers continues
to intensify. Increasingly, providers are looking for ways to better manage
costs in areas such as materials handling, supply utilization, product
standardization for specific procedures and capital expenditures. The new
health-care cost management business is being distributed to stockholders to
more optimally meet these emerging market needs, remove limitations, and improve
the competitiveness of both Baxter and the new company. There has also been
consolidation in the Company's customer base and by its competitors. These
trends are expected to continue. In recent years, the Company's overall price
increases have been below the Consumer Price Index, and industry trends and
competition may inhibit the Company's ability to increase prices in the future.
INTERNATIONAL MARKETS
Throughout the world, as developing countries create more wealth, improving
the health and well-being of their citizens becomes a much higher social
priority and usually leads to increased per-capita spending on health care. The
world's largest developing markets in the Pacific Rim countries and Latin
America are all poised for significant economic growth. Based on these factors,
management believes there will be improved expansion opportunities for the
Company with its broad portfolio of proven cost-effective products, services and
therapies to meet the demands of these markets. In the developed
world--especially in Western Europe and Japan--there continues to be strong
demand for more technologically advanced and cost-effective therapies, products
and services, and the Company has long been a leader in these markets. In view
of these conditions, management believes the Company's best opportunities for
growth are outside the United States. Consequently, the Company's strategies
emphasize international expansion to capitalize on the Company's strong global
positions in intravenous products, renal therapy, biotechnology and
cardiovascular therapies.
HEALTH-CARE COST ENVIRONMENT
Accelerating cost pressures on United States hospitals are resulting in
increased out-patient and alternate-site health-care service delivery and a
focus on cost-effectiveness and quality. In addition, technological advances in
health-care product and service offerings are increasingly evaluated on their
ability to both improve the quality of care and provide more cost-effective
outcomes. These forces increasingly shape the demand for, and supply of, medical
care.
5
Many private health-care payers are providing incentives for consumers to
seek lower cost care outside the hospital. Many corporations' employee health
plans have been restructured to provide financial incentives for patients to
utilize the most cost-effective forms of treatment (managed care programs, such
as health maintenance organizations, have become more common), and physicians
have been encouraged to provide more cost-effective treatments.
The future financial success of health-care product and service companies,
such as the Company, will depend on their ability to work with health-care
customers to help them enhance their competitiveness. The Company believes it
can help its customers achieve savings in the total health-care system by
automating supply-ordering procedures, optimizing distribution networks,
improving materials management and achieving economies of scale associated with
aggregating purchases. The Company continues to believe that its strategy of
providing unmatched service to its health-care customers and achieving the best
overall cost in its delivery of health-care products and services is compatible
with any realignment of the United States health-care system which may
ultimately occur.
Joint Ventures
The Company conducts a portion of its business through joint ventures,
including a joint venture with Nestle, S.A. to develop, market and distribute
clinical nutrition products worldwide. This joint venture is accounted for under
the equity method of accounting and therefore, is excluded from the Company's
segment results.
Methods of Distribution
The Company conducts its selling efforts through its subsidiaries and
divisions. Many subsidiaries and divisions have their own sales forces and
direct their own sales efforts. In addition, sales are made to independent
distributors, dealers and sales agents. Distribution centers, which may serve
more than one division, are stocked with adequate inventories to facilitate
prompt customer service. Sales and distribution methods include frequent contact
by sales representatives, automated communications via various electronic
purchasing systems, circulation of catalogs and merchandising bulletins, direct
mail campaigns, trade publications and advertising.
International sales and distribution are made in approximately 100 countries
either on a direct basis or through independent local distributors.
International subsidiaries employ their own field sales forces in Argentina,
Australia, Austria, Belgium, Brazil, Brunei, Canada, China, Colombia, Ecuador,
Denmark, Finland, France, Germany, Hong Kong, India, Indonesia, Italy, Japan,
Malaysia, Mexico, the Netherlands, New Zealand, Norway, Pakistan, the
Philippines, Singapore, Spain, Sweden, Switzerland, Taiwan, Thailand and the
United Kingdom. In other countries, sales are made through independent
distributors or sales agents.
Raw Materials
Raw materials essential to the Company's business are purchased worldwide in
the ordinary course of business from numerous suppliers. The vast majority of
these materials are generally available, and no serious shortages or delays have
been encountered. Certain raw materials used in producing some of the Company's
products, including its latex products, are available only from a small number
of suppliers. In addition, certain biomaterials for medical implant applications
(primarily polymers) are becoming more difficult to obtain due to market
withdrawals by biomaterial suppliers, primarily as a result of perceived
exposures to liability in the United States.
In some of these situations, the Company has long-term supply contracts with
its suppliers, although it does not consider its obligations under such
contracts to be material. The Company does not always recover cost increases
through customer pricing due to contractual limits and market pressure on such
price increases. See "Contractual Arrangements."
6
Patents and Trademarks
The Company owns a number of patents and trademarks throughout the world and
is licensed under patents owned by others. While it seeks patents on new
developments whenever feasible, the Company does not consider any one or more of
its patents, or the licenses granted to or by it, to be essential to its
business.
Products manufactured by the Company are sold primarily under its own
trademarks and trade names. Some products purchased and resold by the Company
are sold under the Company's trade names while others are sold under trade names
owned by its suppliers.
Competition
Historically, competition in the health-care industry has been characterized
by the search for technological and therapeutic innovations in the prevention,
diagnosis and treatment of disease. The Company believes that it has benefited
from the technological advantages of certain of its products. While others will
continue to introduce new products which compete with those sold by the Company,
the Company believes that its research and development effort will permit it to
remain competitive in all presently material product areas. Although no single
company competes with the Company in all of its businesses, the Company is faced
with substantial competition in all of its markets.
The changing health-care environment in recent years has led to increasingly
intense competition among health-care suppliers. Competition is focused on
price, service and product performance. Pressure in these areas is expected to
continue. See "Health-Care Cost Environment" and "United States Markets."
In part through its restructuring programs, the Company continues to
increase its efforts to minimize costs and better meet accelerating price
competition. The Company believes that its cost position will continue to
benefit from improvements in manufacturing technology and increased economies of
scale. The Company continues to emphasize its investments in innovative and
cost-effective technologies and the quality of its product and services.
Credit and Working Capital Practices
The Company's debt ratings of A3 on senior debt by Moody's, A- by Standard &
Poor's and A by Duff & Phelps were reaffirmed by each rating agency in 1995.
However, the rating agencies have placed the Company on credit watch pending
clarification of the Company's capital structure in conjunction with the
Distribution of the health-care cost management business.
The Company's credit practices and related working capital needs are
comparable to those of other market participants. Collection periods tend to be
longer for sales outside the United States.
Customers may return defective merchandise for credit or replacement. In
recent years, such returns have been insignificant.
Quality Control
The Company places great emphasis on providing quality products and services
to its customers. An integrated network of quality systems, including control
procedures that are developed and implemented by technically trained
professionals, result in rigid specifications for raw materials, packaging
materials, labels, sterilization procedures and overall manufacturing process
control. The quality systems integrate the efforts of raw material and finished
goods suppliers to provide the highest value to customers. On a statistical
sampling basis, a quality assurance organization tests components and finished
goods at different stages in the manufacturing process to assure that exacting
standards are met.
Research and Development
The Company is actively engaged in research and development programs to
develop and improve products, systems and manufacturing methods. These
activities are performed at 21 research and development centers located around
the world and include facilities in Australia, Belgium, Germany,
7
Italy, Japan, Malta, the Netherlands, Sweden, the United Kingdom and the United
States. Expenditures for Company-sponsored research and development activities
related to continuing operations were $345 million in 1995, $303 million in 1994
and $280 million in 1993.
The Company's research efforts emphasize self-manufactured product
development, and portions of that research relate to multiple product lines. For
example, many product categories benefit from the Company's research effort as
applied to the human body's circulatory systems. In addition, research relating
to the performance and purity of plastic materials has resulted in advances that
are applicable to a large number of the Company's products. Principal areas of
strategic focus for research are biotechnology, renal therapy and
transplantation, blood disorders and cardiovascular disease.
Government Regulation
Most products manufactured or sold by the Company in the United States are
subject to regulation by the Food and Drug Administration ("FDA"), as well as by
other federal and state agencies. The FDA regulates the introduction and
advertising of new drugs and devices as well as manufacturing procedures,
labeling and record keeping with respect to drugs and devices. The FDA has the
power to seize adulterated or misbranded drugs and devices or to require the
manufacturer to remove them from the market and the power to publicize relevant
facts. From time to time, the Company has removed products from the market that
were found not to meet acceptable standards. This may occur in the future.
Product regulatory laws exist in most other countries where the Company does
business.
Environmental policies of the Company mandate compliance with all applicable
regulatory requirements concerning environmental quality and contemplate, among
other things, appropriate capital expenditures for environmental protection.
Various non-material capital expenditures for environmental protection were made
by the Company during 1995 and similar expenditures are planned for 1996. See
Item 3.--"Legal Proceedings."
Employees
As of December 31, 1995, the Company employed approximately 56,580 people,
including approximately 31,430 in the United States and Puerto Rico.
Contractual Arrangements
A substantial portion of the Company's products are sold through contracts
with purchasers, both international and domestic. Some of these contracts are
for terms of more than one year and include limits on price increases. In the
case of hospitals, clinical laboratories and other facilities, these contracts
may specify minimum quantities of a particular product or categories of products
to be purchased by the customer.
(d) FINANCIAL INFORMATION ABOUT FOREIGN AND DOMESTIC OPERATIONS AND EXPORT
SALES.
International operations are subject to certain additional risks inherent in
conducting business outside the United States, such as changes in currency
exchange rates, price and currency exchange controls, import restrictions,
nationalization, expropriation and other governmental action.
Financial information is incorporated by reference from the Annual Report,
pages 68-69, section entitled "Notes to Consolidated Financial
Statements--Industry and Geographic Information."
8
- --------------------------------------------------------------------------------
ITEM 2. PROPERTIES.
The Company owns or has long-term leases on substantially all of its major
manufacturing facilities. The Company maintains 33 manufacturing facilities in
the United States, including seven in Puerto Rico, and also manufactures in
Australia, Belgium, Brazil, Canada, the Czech Republic, Chile, China, Colombia,
Costa Rica, the Dominican Republic, France, Ireland, Italy, Japan, Malaysia,
Malta, Mexico, the Netherlands, Singapore, Spain, Russia, Turkey and the United
Kingdom.
The Company owns or operates 83 distribution centers in the United States
and Puerto Rico and 66 located in 22 foreign countries.
The Company maintains a continuing program for improving its properties,
including the retirement or improvement of older facilities and the construction
of new facilities. This program includes improvement of manufacturing facilities
to enable production and quality control programs to conform with the current
state of technology and government regulations. Capital expenditures related to
continuing operations were $309 million in 1995, $308 million in 1994 and $276
million in 1993. In addition, the Company added to the continuing operations
pool of equipment leased or rented to customers, spending $90 million in 1995,
$72 million in 1994 and $56 million in 1993.
- --------------------------------------------------------------------------------
ITEM 3. LEGAL PROCEEDINGS.
Incorporated by reference from the Annual Report, pages 62-68, section
entitled "Notes to Consolidated Financial Statements--Legal Proceedings."
Additionally, in March 1996, and after the Annual Report was printed, the courts
in Osaka and Tokyo issued second settlement plans and second interim opinions in
the Japanese Factor Concentrate cases. Those plans and opinions supplement the
courts' original plans for resolution of the litigation by confirming the
approximate $450,000 up-front payment to each plaintiff, which is to be funded
60% by the corporate defendants and 40% by the Japanese government. The courts'
plans and opinions also establish on-going payments to AIDS-manifested
hemophiliacs at $1,500 per month and set attorneys' fees at $35,000 per current
plaintiff and $15,000 per future plaintiff. The courts' plans provide that the
Japanese government will fund 40% of those amounts, and that the corporate
defendants will fund 60% with the corporate defendants funding their amounts in
proportion to their 1983 market shares, resulting in the Company paying 12.5% of
the overall corporate defendants' share. The courts' plans also provide for the
continuation of the Yuai Zaidan for non-plaintiffs through March 2001, for the
Japanese government to fund 40% of the aggregate amount required for the Yuai
Zaidan, for 100% credit of future Yuai Zaidan payments to individuals against
settlement amounts paid after the settlement is approved, and for the entry of
future plaintiffs into the fund. On March 13, 1996, the Company accepted the
basic terms of the courts' imposed settlement. Negotiations on the details of
the settlement are continuing.
- --------------------------------------------------------------------------------
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
None.
9
PART II
- --------------------------------------------------------------------------------
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS.
Incorporated by reference from the Annual Report, page 70, section entitled
"Notes to Consolidated Financial Statements--Quarterly Financial Results and
Market for the Company's Stock."
- --------------------------------------------------------------------------------
ITEM 6. SELECTED FINANCIAL DATA.
Incorporated by reference from the Annual Report, inside back cover, section
entitled "Five Year Summary of Selected Financial Data."
- --------------------------------------------------------------------------------
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Incorporated by reference from the Annual Report, pages 30-43, section
entitled "Management's Discussion and Analysis."
- --------------------------------------------------------------------------------
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
Incorporated by reference from the Annual Report, pages 45-70, sections
entitled "Report of Independent Accountants," "Consolidated Balance Sheets,"
"Consolidated Statements of Income," "Consolidated Statements of Cash Flows,"
"Consolidated Statements of Stockholders' Equity," and "Notes to Consolidated
Financial Statements."
- --------------------------------------------------------------------------------
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
None.
10
PART III
- --------------------------------------------------------------------------------
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
(a) IDENTIFICATION OF DIRECTORS
Incorporated by reference from the board of directors' proxy statement for
use in connection with Baxter's annual meeting of stockholders to be held on May
6, 1996 (the "Proxy Statement"), pages x-x, sections entitled "Board of
Directors" and "Election of Directors."
(b) IDENTIFICATION OF EXECUTIVE OFFICERS
Following are the names and ages, as of March 1, 1996, of the executive
officers of Baxter International Inc. ("Baxter"), and one or both of its two
principal direct subsidiaries, Baxter Healthcare Corporation ("Healthcare") and
Baxter World Trade Corporation ("World Trade"), their positions and summaries of
their backgrounds and business experience. All executive officers of Baxter are
elected or appointed by the board of directors and hold office until the next
annual meeting of directors and until their respective successors are elected
and qualified. The annual meeting of directors is held after the annual meeting
of stockholders. All executive officers of Healthcare and World Trade are
elected or appointed by the boards of directors of the applicable subsidiary and
hold office until their respective successors are elected and qualified. As
permitted by applicable law, actions by these boards (and their sole
stockholder, Baxter) may be taken by written consent in lieu of a meeting.
(1) BAXTER INTERNATIONAL INC. EXECUTIVE OFFICERS
VERNON R. LOUCKS JR., age 61, has been chairman of the board of directors
since 1987 and chief executive officer of Baxter since 1980. Mr. Loucks was
first elected an officer of Baxter in 1971.
MANUEL A. BAEZ, age 54, has been an executive vice president of Baxter since
1995, and a group vice president of World Trade since 1994. Between 1990 and
1994, Mr. Baez was a group vice president of Baxter. Mr. Baez was first elected
an officer of Baxter in 1989.
LESTER B. KNIGHT, age 37, has been an executive vice president of Baxter
since 1992, and a corporate vice president since 1990, when he was first elected
an officer.
HARRY M. JANSEN KRAEMER, Jr., age 41, has been a senior vice president and
chief financial officer of Baxter since 1993. Mr. Kraemer previously was the
vice president of finance and operations for a subsidiary of Baxter. Prior to
that he was employed as controller, group controller, and president of various
divisions of subsidiaries of Baxter.
ARTHUR F. STAUBITZ, age 56, has been senior vice president and general
counsel of Baxter since 1993. From 1993 to 1994, he was also secretary of
Baxter. Mr. Staubitz previously was vice president/general manager of the
ventures group of a subsidiary of Baxter. Prior to that he was senior vice
president, secretary and general counsel of Amgen, Inc. Prior to that he was a
vice president of a Baxter subsidiary, and prior to that he was a vice president
and deputy general counsel of Baxter.
MICHAEL J. TUCKER, age 43, has been senior vice president of Baxter since
1995. From 1994 to 1995, he was a corporate vice president of World Trade. Mr.
Tucker previously was a vice president of a division of World Trade, and prior
to that, was a vice president of another division of a subsidiary of Baxter.
HERBERT E. WALKER, age 61, has been senior vice president of Baxter since
1993. Mr. Walker previously was vice president of human resources of a division
of Healthcare.
FABRIZIO BONANNI, age 49, has been a vice president of Baxter since 1995.
From 1994 to 1995, he was a corporate vice president of World Trade. Mr. Bonanni
previously was a vice president of a division of World Trade.
11
JOHN F. GAITHER, Jr., age 46, has been a vice president of Baxter since
1994. Between 1991 and 1994, Mr. Gaither was vice president of law and strategic
planning for a subsidiary of Baxter, and prior to that, was secretary and deputy
general counsel of Baxter.
DAVID C. MCKEE, age 48, has been a vice president of Baxter since 1996.
Between 1994 and 1996, Mr. McKee was Baxter's deputy general counsel, and prior
to that, was associate general counsel of a subsidiary of Baxter.
KSHITIJ MOHAN, age 51, has been a vice president of Baxter since 1995. In
1995, Mr. Mohan also was a corporate vice president of World Trade. Mr. Mohan
previously was a vice president of a division of Healthcare.
JOHN L. QUICK, age 51, has been a vice president of Baxter since 1995. From
1994 to 1995, he was a corporate vice president of Healthcare. Mr. Quick
previously was a vice president of a division of Healthcare, and prior to that,
was a vice president of another division of that subsidiary.
KATHY B. WHITE, age 46, has been vice president and chief information
officer of Baxter since 1995. Ms. White previously was vice president of
information systems of Allied Signal Corporation, and prior to that, was a
corporate officer responsible for human resources and information systems with
Guilford Mills, Inc.
BRIAN P. ANDERSON, age 45, has been controller of Baxter since 1993. Mr.
Anderson previously was the vice president of corporate audit of a subsidiary of
Baxter, and prior to that was a partner in the international accounting firm of
Deloitte & Touche.
LAWRENCE D. DAMRON, age 49, has been treasurer of Baxter since 1992. Mr.
Damron previously was a vice president and controller of a division of a
subsidiary of Baxter, and prior to that was the corporate auditor of another
subsidiary. Prior to that, he was vice president and controller of a division of
that subsidiary.
A. GERARD SIECK, age 39, has been secretary of Baxter since 1994. Between
1992 and 1994, Mr. Sieck was assistant secretary of Baxter, and prior to that,
was corporate counsel in the law department of Healthcare.
(2) HEALTHCARE AND WORLD TRADE EXECUTIVE OFFICERS
TIMOTHY B. ANDERSON, age 49, has been a group vice president of Healthcare
and World Trade since 1994. Between 1992 and 1994, Mr. Anderson was a vice
president of Baxter. Mr. Anderson previously was president of several divisions
of a subsidiary of Baxter.
JOSEPH F. DAMICO, age 42, has been a group vice president of Healthcare
since 1994. Between 1992 and 1994, Mr. Damico was a vice president of Baxter.
Mr. Damico previously was president of a division of Healthcare, and prior to
that was a vice president - general manager of that division.
DONALD W. JOSEPH, age 58, has been a group vice president of Healthcare and
World Trade since 1994. Between 1990 and 1994, Mr. Joseph was a vice president
of Baxter.
JACK L. MCGINLEY, age 49, has been a group vice president of Healthcare
since 1994. Between 1992 and 1994, Mr. McGinley was a vice president of Baxter.
Mr. McGinley previously was president of a division of Healthcare, and prior to
that was president of the Japanese subsidiary of World Trade.
TERRENCE J. MULLIGAN, age 50, has been a group vice president of Healthcare
since 1994. Between 1990 and 1994, Mr. Mulligan was a senior vice president of
Baxter. Mr. Mulligan was first elected an officer of Baxter in 1985.
MICHAEL A. MUSSALLEM, age 43, has been a group vice president of Healthcare
since 1994. From 1993 to 1994, Mr. Mussallem was president of a division of
Healthcare, and from 1990 to 1993, was president of another division of that
subsidiary.
12
CARLOS DEL SALTO, age 53, has been a corporate vice president of World Trade
since 1994. Between 1992 and 1994, Mr. del Salto was a vice president of Baxter.
Mr. del Salto previously was president-- Latin America/Switzerland/Austria of a
subsidiary of Baxter, and prior to that, he was vice president-- Latin America
of that subsidiary.
J. ROBERT HURLEY, age 46, has been a corporate vice president of World Trade
since 1993. Mr. Hurley previously was vice president of a division of World
Trade.
ROBERTO E. PEREZ, age 46, has been a corporate vice president of Healthcare
and World Trade since March 3, 1995. Between 1992 to 1995, Mr. Perez was
president of a division of a subsidiary of Baxter, and prior to that was a vice
president of that division.
(c) COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934.
Incorporated by reference from Proxy Statement, page 18, section entitled
"Section 16 Reporting."
- --------------------------------------------------------------------------------
ITEM 11. EXECUTIVE COMPENSATION.
Incorporated by reference from the Proxy Statement, pages 6-16, sections
entitled "Compensation of Directors" and "Compensation of Named Executive
Officers," and pages 17-18, section entitled "Pension Plan, Excess Plans and
Supplemental Plans."
- --------------------------------------------------------------------------------
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
Incorporated by reference from the Proxy Statement, pages 18-20, section
entitled "Ownership of Company Securities."
- --------------------------------------------------------------------------------
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
None.
13
- --------------------------------------------------------------------------------
PART IV
- --------------------------------------------------------------------------------
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
The following documents are filed as a part of this report:
(a) Financial Statements Location
FINANCIAL STATEMENTS REQUIRED BY ITEM 8 OF THIS FORM
Consolidated Balance Sheets Annual Report, page 46
Consolidated Statements of Income Annual Report, page 47
Consolidated Statements of Cash Flows Annual Report, page 48
Consolidated Statements of Stockholders' Equity Annual Report, page 49
Annual Report, pages
Notes to Consolidated Financial Statements 50-70
Report of Independent Accountants Annual Report, page 45
SCHEDULES REQUIRED BY ARTICLE 12 OF REGULATION S-X
Report of Independent Accountants on Financial Statement
Schedule page 15
II Valuation and Qualifying Accounts page 16
All other schedules have been omitted because they are not applicable or not required.
(b) Reports on Form 8-K
A report on Form 8-K, dated November 14, 1995, was filed with the SEC under Item 5,
Other Events, to file a press release which announced, among other things, a $500
million stock repurchase program and participation in a revised settlement of
mammary-implant litigation.
A report on Form 8-K, dated November 28, 1995, was filed with the SEC under Item 5,
Other Events, to file a press release which announced a plan to distribute to Baxter
shareholders publicly-traded stock for a new health-care cost management company.
A report on Form 8-K, dated February 2, 1996, was filed with the SEC under Item 5,
Other Events, to file a press release which announced an offer to acquire the
National Medical Care, Inc. subsidiary of W. R. Grace & Co.
A report on Form 8-K, dated February 29, 1996, was filed with the SEC under Item 5,
Other Events, to file a press release which announced the withdrawal of a February
2, 1996 offer to acquire the National Medical Care, Inc. subsidiary of W. R. Grace &
Co.
(c) Exhibits required by Item 601 of Regulation S-K are listed in the Exhibit Index,
which is incorporated herein by reference.
14
REPORT OF INDEPENDENT ACCOUNTS ON THE FINANCIAL STATEMENT SCHEDULE
- --------------------------------------------------------------------------------
To the Board of Directors of
Baxter International Inc.
Our audits of the consolidated financial statements referred to in our
report dated February 14, 1996 appearing on page 45 of the 1995 Annual Report to
Stockholders of Baxter International Inc. (which report and consolidated
financial statements are incorporated by reference in the Annual Report on Form
10-K) also included an audit of the Financial Statement Schedule listed in Item
14(a) of this Form 10-K. In our opinion, this Financial Statement Schedule
presents fairly, in all material respects, the information set forth therein
when read in conjunction with the related consolidated financial statements.
PRICE WATERHOUSE LLP
Chicago, Illinois
February 14, 1996
15
SCHEDULE II
- --------------------------------------------------------------------------------
VALUATION AND QUALIFYING ACCOUNTS
(In millions of dollars)
- -----------------------------------------------------------------------------------------------------------------------------
ADDITIONS
------------------------------
BALANCE AT CHARGED TO CHARGED TO BALANCE AT
BEGINNING COSTS AND OTHER DEDUCTIONS END OF
DESCRIPTION OF PERIOD EXPENSES ACCOUNTS(A) FROM RESERVES PERIOD
- -----------------------------------------------------------------------------------------------------------------------------
YEAR ENDED DECEMBER 31, 1995:
Accounts receivable $ 21 $ 9 $ 1 $ (9) $ 22
--
--
--- --- --- ---
--- --- --- ---
- -----------------------------------------------------------------------------------------------------------------------------
YEAR ENDED DECEMBER 31, 1994:
Accounts receivable $ 19 $ 7 $ 1 $ (6) $ 21
--
--
--- --- --- ---
--- --- --- ---
- -----------------------------------------------------------------------------------------------------------------------------
YEAR ENDED DECEMBER 31, 1993:
Accounts receivable $ 16 $ 6 $ (1) $ (2) $ 19
--
--
--- --- --- ---
--- --- --- ---
- -----------------------------------------------------------------------------------------------------------------------------
(A) Valuation accounts of acquired or divested companies and foreign currency
translation adjustments. Reserves are deducted from assets to which they
apply.
16
SIGNATURES
Pursuant to the requirements of section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
BAXTER INTERNATIONAL INC.
By: /s/ VERNON R. LOUCKS JR.
----------------------------------
Vernon R. Loucks Jr.
CHAIRMAN OF THE BOARD AND
CHIEF EXECUTIVE OFFICER
Date: March 21, 1996
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the date indicated.
(i) Principal Executive Officer: (iv) A Majority of the Board of Directors
Silas S. Cathcart
/S/ VERNON R. LOUCKS JR. Pei-yuan Chia
-----------------------
Vernon R. Loucks Jr. John W. Colloton
DIRECTOR, CHAIRMAN OF THE BOARD Susan Crown
AND CHIEF EXECUTIVE OFFICER Mary Johnston Evans
Frank R. Frame
David W. Grainger
Martha R. Ingram
Lester B. Knight
Harry M. Jansen Kraemer, Jr.
(ii) Principal Financial Officer: Arnold J. Levine
Georges C. St. Laurent, Jr.
Monroe E. Trout, M.D.
/S/ HARRY M. JANSEN KRAEMER, JR. Fred L. Turner
--------------------------------
Harry M. Jansen Kraemer, Jr.
SENIOR VICE PRESIDENT AND
CHIEF FINANCIAL OFFICER
(iii) Controller:
/s/ BRIAN P. ANDERSON By: /s/ VERNON R. LOUCKS JR.
--------------------- ----------------------------
Brian P. Anderson Vernon R. Loucks Jr.
CONTROLLER DIRECTOR AND ATTORNEY-IN-FACT
17
- --------------------------------------------------------------------------------
APPENDICES
DESCRIPTION PAGE
- ------------------------------------------------------------------------------------------------------ ---------
Computation of Primary Earnings per Common Share (Exhibit 11.1) 22
Computation of Fully Diluted Earnings per Common Share (Exhibit 11.2) 23
Computation of Ratio of Earnings to Fixed Charges (Exhibit 12) 24
Subsidiaries of the Company (Exhibit 21) 25
- --------------------------------------------------------------------------------
EXHIBITS FILED WITH SECURITIES AND EXCHANGE COMMISSION
NUMBER AND DESCRIPTION OF EXHIBIT
- --------------------------------------------------------------------------------------------------------------------
3. Certificate of Incorporation and Bylaws
3.1* Restated Certificate of Incorporation, filed as exhibit 3.1 to the Company's annual report on
Form 10-K for the year ended December 31, 1992, file number 1-4448 (the "1992 Form 10-K").
3.2* Certificate of Designation of Series A Junior Participating Preferred Stock, filed under the
Securities Act of 1933 as exhibit 4.3 to the Company's registration statement on Form S-8 (No.
33-28428).
3.3* Amended and Restated Bylaws, filed as exhibit 3.3 to the Form 10-Q for the quarter ended
September 30, 1994, file number 1-4448.
4. Instruments defining the rights of security holders, including indentures
4.1* Indenture for 4 3/4% Convertible Subordinated Debentures due January 1, 2001, filed under the
Securities Act of 1933 as exhibit 2(d) to the Company's registration statement on Form S-7
(No. 2-55622).
4.2* Indenture dated November 15, 1985 between the Company and Bankers Trust Company, filed as
exhibit 4.8 to the Company's current report on Form 8-K dated December 16, 1985, file no.
1-4448.
4.3* Amended and Restated Indenture dated November 15, 1985, between the Company and Continental
Illinois National Bank and Trust Company of Chicago, filed under the Securities Act of 1933 as
exhibit 4.1 to the Company's registration statement on Form S-3 (No. 33-1665).
4.4* First Supplemental Indenture to Amended and Restated Indenture dated November 15, 1985,
between the Company and Continental Illinois National Bank and Trust Company of Chicago, filed
under the Securities Act of 1933 as exhibit 4.1(A) to the Company's registration statement on
Form S-3 (No. 33-6746).
4.5* Indenture dated as of August 15, 1977, between the Company and Midlantic National Bank, as
supplemented, filed as exhibit 4.7 to the Company's annual report on Form 10-K for the year
ended December 31, 1985, file no. 1-4448 (the "1985 Form 10-K").
4.6* Fiscal and Paying Agency Agreement dated as of April 26, 1984, among American Hospital Supply
International Finance N.V., the Company and The Toronto-Dominion Bank, as amended, filed as
exhibit 4.9 to the 1985 Form 10-K.
4.7* Fiscal and Paying Agency Agreement dated as of November 15, 1984, between the Company and
Citibank, N.A., as amended, filed as exhibit 4.16 to the Company's annual report on Form 10-K
for the year ended December 31, 1987, file no. 1-4448 (the "1987 Form 10-K").
4.8* Specimen Medium-Term Note, filed as exhibit 4.10 to the 1985 Form 10-K.
4.9* Specimen Extendible Note, filed as exhibit 4.11 to the 1985 Form 10-K.
18
NUMBER AND DESCRIPTION OF EXHIBIT
- --------------------------------------------------------------------------------------------------------------------
4.10* Specimen 13 1/8% Note, filed as exhibit 4.12 to the 1985 Form 10-K.
4.11* Specimen 9 5/8% Note, filed as exhibit 4.13 to the 1987 Form 10-K.
4.12* Specimen 8 7/8% Debenture, filed as exhibit 4.2(a) to the Company's current report on Form 8-K
dated June 15, 1988, file no. 1-4448.
4.13* Specimen 9 1/2% Note, filed as exhibit 4.3(a) to the Company's current report on Form 8-K
dated June 23, 1988, file no. 1-4448.
4.14* Specimen 9 1/4% Note, filed as exhibit 4.3(a) to the Company's current report on Form 8-K
dated September 13, 1989, file number 1-4448.
4.15* Specimen 9 1/4% Note, filed as exhibit 4.3(a) to the Company's current report on Form 8-K
dated December 7, 1989, file number 1-4448.
10. Material Contracts
10.1* Employment Agreement between William B. Graham and the Company, filed as exhibit 10.1 to the
1985 Form 10-K.
10.2* Form of Indemnification Agreement entered into with directors and officers, filed as exhibit
19.4 to the Company's quarterly report on Form 10-Q for the quarter ended September 30, 1986,
file no. 1-4448.
10.3* Stock Option Plan of 1977 (as amended and restated), filed as exhibit 19.3 to the Company's
quarterly report on Form 10-Q for the quarter ended September 30, 1984, file no. 1-4448.
10.4* 1988 Long-Term Incentive Plan, filed as exhibit 10.12 to the 1987 Form 10-K.
10.5* 1987-1989 Long-Term Performance Incentive Plan, filed as exhibit 10.15 to the Company's annual
report on Form 10-K for the year ended December 31,1986 (the "1986 Form 10-K").
10.6* 1989 Long-Term Incentive Plan, filed as exhibit 10.12 to the Company's annual report on Form
10-K for the year ended December 31, 1988, file no. 1-4448 (the "1988 Form 10-K").
10.7* Stock Option Plan Adopted July 25, 1988, filed as exhibit 10.13 to the 1988 Form 10-K.
10.8* 1991 Officer Incentive Compensation Plan, filed as exhibit 10.11 to the Company's annual
report on Form 10-K for the year ended December 31, 1990, file number 1-4448 (the "1990 Form
10-K").
10.9* Baxter International Inc. and Subsidiaries Incentive Investment Excess Plan, filed as exhibit
10.17 to the 1988 Form 10-K.
10.10* Baxter International Inc. and Subsidiaries Supplemental Pension Plan, filed as exhibit 10.18
to the 1988 Form 10-K.
10.11* Amendment to Stock Option Plan of 1977, filed as exhibit 19.2 to the Company's quarterly
report on Form 10-Q for the quarter ended September 30, 1989, file no. 1-4448 (the "September,
1989 Form 10-Q").
10.12* Limited Rights Plan, filed as exhibit 19.6 to the September, 1989 Form 10-Q.
10.13* Amendments to various plans regarding disability, filed as exhibit 19.9 to the September, 1989
Form 10-Q.
10.14* Amendments to 1987-1989 Long-Term Performance Incentive Plan and 1988 Long-Term Incentive
Plan, filed as exhibit 19.10 to the September, 1989 Form 10-Q.
19
NUMBER AND DESCRIPTION OF EXHIBIT
- --------------------------------------------------------------------------------------------------------------------
10.15* 1987 Incentive Compensation Program, filed as exhibit C to the Company's proxy statement for
use in connection with its May 13, 1987, annual meeting of stockholders, file no. 1-4448.
10.16* Rights Agreement between the Company and The First National Bank of Chicago, filed as exhibit
1 to a registration statement on Form 8-A dated March 21, 1989, file no. 1-4448.
10.17* Amendment to 1987 Incentive Compensation Program, filed as exhibit 19.1 to September, 1989
Form 10-Q.
10.18* Deferred Compensation Plan (1990), filed as exhibit 10.24 to the 1990 Form 10-K.
10.19* Restricted Stock Grant Terms and Conditions, filed as exhibit 10.25 to the Company's annual
report on Form 10-K for the year ended December 31, 1991, file number 1-4448 (the "1991 Form
10-K").
10.20* Vernon R. Loucks Restricted Stock Grant Terms and Conditions, filed as exhibit 10.26 to the
1991 Form 10-K.
10.21* Deferred Compensation Plan (1990), as amended in 1992, filed as exhibit 10.27 to the 1992 Form
10-K.
10.22* Restricted Stock Plan for Non-Employee Directors (as amended and restated in 1992), filed as
exhibit 10.28 to the 1992 Form 10-K.
10.23* Restricted Stock Grant Terms and Conditions (as amended), filed as exhibit 10.31 to the 1992
Form 10-K.
10.24* 1992 Officer Incentive Compensation Plan, filed as exhibit 10.29 to the 1992 Form 10-K.
10.25* 1993 Officer Incentive Compensation Plan, filed as exhibit 10.30 to the 1992 Form 10-K.
10.26* 1994 Officer Incentive Compensation Plan, filed as exhibit 10.31 to the Company's annual
report on Form 10-K for the year ended December 31, 1993, file number 1-4448 (the "1993 Form
10-K").
10.27* Corporate Aviation Policy, filed as exhibit 10.33 to the 1992 Form 10-K.
10.28* Plan and Agreement of Reorganization Between Baxter and Caremark International Inc., filed as
exhibit 10.34 to the 1992 Form 10-K
10.29* 1994 Incentive Compensation Program, filed as exhibit A to the Company's proxy statement for
use in connection with its April 29, 1994 annual meeting of stockholders, file no. 1-4448.
10.30* 1994 Shared Investment Plan and Terms and Conditions, filed as exhibit 10.1 to the Company's
quarterly report on Form 10-Q for the quarter ended June 30, 1994.
10.31* 1995 Officer Incentive Compensation Plan, filed as exhibit 10.31 to the Company's annual
report on Form 10-K for the year ended December 31, 1994 (the "1994 Form 10-K").
10.32* Baxter International Inc. Restricted Stock Plan for Non-Employee Directors, as amended and
restated effective May 8, 1995, filed as exhibit 10.32 to the 1994 Form 10-K.
10.33 1996 Officer Incentive Compensation Plan.
10.34 1995 Stock Option Plan Terms and Conditions.
10.35 Separation Agreement: Tony L. White.
10.36 Separation Agreement: Manuel A. Baez
20
NUMBER AND DESCRIPTION OF EXHIBIT
- --------------------------------------------------------------------------------------------------------------------
11. Statement re: computation of per share earnings.
11.1 Computation of primary earnings per common share.
11.2 Computation of fully diluted earnings per common share.
12. Statements re: computation of ratios.
13. 1995 Annual Report to Stockholders (such report, except to the extent incorporated herein by reference,
is being furnished for the information of the Securities and Exchange Commission only and is not deemed
to be filed as part of this annual report on Form 10-K).
21. Subsidiaries of the Company.
23. Consent of Price Waterhouse.
24. Powers of Attorney.
27. Financial Statement Schedule.
- ------------------------
* Incorporated herein by reference.
(All other exhibits are inapplicable.)
21